Abstract library

10 results for "Fiori".
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
Authors:
#1358 Identifying and Prioritising Gaps in Neuroendocrine Tumour Research - Results of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)
Introduction: The newly formed CommNETS group used the robust Delphi methodology with broad stakeholder engagement to form a strategic research agenda.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: A/P Eva Segelov
Authors:
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
Authors:
#1214 Initial Experience with Robot-Assisted Distal Pancreatectomy for Pancreatic Neuroendocrine Neoplasms
Introduction: Robot-assisted distal pancreatectomy (RADP) for pancreatic neuroendocrine neoplasms (pNEN) has not been investigated so far
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Authors:
#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
Authors:
Keywords: PRRT, FDG-PET, P-NET
#1323 Expression of Oncofetal Protein IMP3 in Lymph Node Metastases of Small Intestine Neuroendocrine Neoplasms: A New Predictor of Recurrence
Introduction: Small intestine neuroendocrine neoplasm (SINENs) are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki67 is the main determinant of prognosis in NENs. However, the research for new prognostic makers represent a key-point. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: dr Sara Massironi
Authors:
Keywords: IMP3, intestinal NENs
#2213 Imaging Modality Depending on the Levels of Tumor Markers
Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: DOCTOR Julieta Iorio
Authors:
#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance
Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden
Authors:
#1049 Optimal Surgical Treatment of Pancreatic Neuroendocrine Tumors
Introduction: For pancreatic neuroendocrine tumors (pNET), different types of pancreatic resections are available.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Anneke Jilesen
Authors:
#2193 Advanced Gastric Neuroendocrine Carcinoma: A Diagnostic and Management Conundrum
Introduction: Gastric neuroendocrine carcinomas are rare tumors with a high malignant trait and poor prognosis. Endogenous hypercortisolism associated with neuroendocrine carcinomas can have a negative impact on patients' survival.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Ioana Maria Lambrescu
Authors: